AstraZeneca Presents Results of Calquence in the P-III (ASCEND) Trial for the Treatment of Chronic Lymphocytic Leukaemia at ASH 2021
Shots:
- The P-III (ASCEND) trial evaluates the efficacy & safety of Calquence (100mg, bid) vs IdR or BR in a ratio (1:1) in 310 patients with r/r CLL
- The results showed a PFS benefit @3yrs., 71% reduction in risk of disease progression or death, similar clinical benefits were observed in an exploratory analysis, safety & tolerability were consistent with earlier findings & no new safety signals were observed, treatment discontinuation due to AEs (21%), 65% & 17% of patients on IdR & BR
- The company also presents additional safety analyses from the P-III (ELEVATE-RR) trial of Calquence vs ibrutinib which showed that patients experienced a 37% higher burden of AEs of any grade over Calquence
Ref: AstraZeneca | Image: Mint
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com